A two-year clinical trial discussed in November 2026 reported an increase of 49 coronary artery calcium score points in a vitamin K2 group, versus 69 points in the placebo group. The difference has attracted attention, but the headline numbers alone do not establish a cardiovascular benefit.
What coronary calcium measures
Coronary artery calcium scoring is a CT-based measure of calcified plaque burden. Changes in scores can be influenced by baseline risk and other factors; the clinical meaning of a between-group difference depends on the trial design, statistical analysis and patient outcomes.
Why caution is necessary
Without reviewing the full peer-reviewed trial and prespecified endpoints, it is premature to conclude that vitamin K2 prevents heart attacks or reverses plaque. Vitamin K is also clinically relevant to people taking vitamin K-antagonist anticoagulants, who should seek medical guidance before changing intake.
Formulation and claims implications
For developers, MK-7 stability, dose uniformity, matrix interactions and validated assays matter as much as the ingredient story. Marketing should distinguish a biological hypothesis from a demonstrated reduction in cardiovascular events.
Source and editorial note
Read the original reporting and research context. This independent editorial summary was prepared on 17 November 2026. It is not medical advice. Research findings do not establish that supplements prevent, treat or cure disease.








